Influenza A virus (IAV) is an RNA virus that can infect humans and also animals such as birds and pigs with high infectivity. Although there are several groups of anti-IAV drugs in the market, there is a need for new strategies due to the emergence of resistance and the high variability of the virus. One of the potential targets to watch in this disease is hemagglutinin (HA).

Vaccines now in clinical trials can raise broad-spectrum antibodies against more than one form of hemagglutinin and provide protection against the flu strains that have been most troublesome from a public health perspective.